Ergoteles’s Jade Biosciences JBIO Stock Holding History

Ergoteles’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-302	Closed	-$175K	–	1444
2022 Q3	$175K	Sell	302 -212	-41%	-$142K	0.01%	1228
2022 Q2	$281K	Buy	+514	New	+$245K	0.01%	1138

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Ergoteles's JBIO Position: Q4 2022 in Review

Ergoteles sold out of Jade Biosciences (JBIO) in Q4 2022, closing a stake of 302 shares — an estimated $175K sold.

Ergoteles first reported a position in JBIO in Q2 2022 and held it in 2 quarters. The position peaked at $281K in Q2 2022. 68 funds tracked by Wall St. Rank hold JBIO as of Q4 2022.

Ergoteles reported no remaining Jade Biosciences position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 302 Jade Biosciences shares in Q4 2022, an estimated $175K.
Ergoteles first reported a position in Jade Biosciences in Q2 2022 and held it in 2 quarters.
Ergoteles's Jade Biosciences position peaked at $281K in Q2 2022.
68 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.